Kiniksa Pharmaceuticals (NASDAQ:KNSA) Issues Quarterly Earnings Results

Kiniksa Pharmaceuticals (NASDAQ:KNSA) released its earnings results on Tuesday. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05, Zacks reports. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals updated its FY 2025 guidance to EPS.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $24.50 on Tuesday. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -173.95 and a beta of 0.31. The stock’s 50 day moving average price is $21.19 and its 200 day moving average price is $21.28. Kiniksa Pharmaceuticals has a 12 month low of $17.38 and a 12 month high of $28.15.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the sale, the chief financial officer now owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 27.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ross Moat sold 18,259 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $20.29, for a total value of $370,475.11. Following the completion of the sale, the insider now owns 9,415 shares of the company’s stock, valued at $191,030.35. This trade represents a 65.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 110,025 shares of company stock worth $2,372,610. Corporate insiders own 54.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KNSA. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.